LENZ Therapeutics Faces Critical Test as Losses Widen and Stock Plunges

Lenz Therapeutics reports fourth-quarter 2025 earnings before the open on March 24, 2026. With analysts expecting a loss of $0.91 per share—nearly double the year-ago loss—and the stock down sharply from recent highs, investors will scrutinize the company's VIZZ launch trajectory and cash runway as it navigates a pivotal commercialization phase.

Part 1: Earnings Preview

Lenz Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic conditions, with its lead product VIZZ targeting presbyopia (age-related loss of near vision). The company recently launched VIZZ commercially and is scaling its sales force to drive adoption.

Analysts expect LENZ to report a loss of $0.91 per share for the fourth quarter of 2025, with six analysts covering the stock. The company most recently reported a loss of $0.59 per share in the third quarter of 2025. Compared to the same quarter last year, when LENZ posted a loss of $0.46 per share, the expected loss represents a 97.83% deterioration year-over-year—reflecting the significant cash burn associated with the VIZZ commercial launch.

Three key themes define this earnings story:

VIZZ Launch Momentum: Investors will focus intensely on prescription growth, patient adoption metrics, and early commercial traction. Recent news indicates LENZ has expanded its sales force to 117 representatives and outlined a 2026 acceleration strategy, suggesting management is investing aggressively in the launch. The question is whether script volumes justify the spending.

Cash Runway and Burn Rate: With losses widening substantially, the company's $292 million cash position and quarterly burn rate will be critical. Analysts will assess whether LENZ has sufficient runway to reach profitability or whether additional financing may be needed, which could dilute shareholders.

Market Reaction to Widening Losses: The stock has crashed recently, with one news headline noting "Why Lenz Therapeutics Stock Crashed Today." Investors are clearly concerned about the pace of losses relative to revenue generation. Management's guidance on the path to profitability will be essential to restoring confidence.

Leading analysts have been revising their expectations ahead of the release, with Benzinga reporting that "Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings." The consensus has shifted notably, with the prior estimate for this quarter at just $0.46 per share—meaning analysts have nearly doubled their expected loss in recent months as they factor in higher commercialization costs.

Part 2: Historical Earnings Performance

LENZ has demonstrated a consistent pattern of beating estimates over the past four quarters, though the magnitude of beats has been modest and the absolute losses have been growing. In the most recent quarter (September 2025), the company reported a loss of $0.59 versus an estimate of $0.67, representing an 11.94% beat—the largest positive surprise in the recent history. The prior two quarters also saw beats of 8.62% and 3.64%, respectively.

However, the December 2024 quarter showed a 9.52% miss, with a reported loss of $0.46 against an estimate of $0.42. This suggests that while LENZ has recently improved its ability to manage costs relative to expectations, the company has not always been predictable. The trend of widening losses is clear: from $0.46 four quarters ago to $0.59 most recently, with the current quarter expected at $0.91—a trajectory that reflects the heavy investment phase of the VIZZ launch.

The pattern suggests analysts may still be underestimating the cash burn associated with commercialization, though recent estimate revisions (from $0.46 to $0.91 for this quarter) indicate they are catching up to the reality of launch costs.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

LENZ typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, and Day +1 captures follow-through momentum.

LENZ has shown highly volatile post-earnings price action, with an average absolute Day 0 move of 6.93% and Day +1 move of 3.56%. The most dramatic reaction came in November 2025, when the stock plunged 23.46% on earnings day following a disappointing report, though it partially recovered with a 6.94% gain the next session. Earlier in 2024, the stock surged 12.50% on earnings day in November, demonstrating the wide range of possible outcomes.

The intraday volatility is also notable, with Day 0 trading ranges averaging 8.72% and Day +1 ranges averaging 10.81%—indicating significant intraday swings as investors digest results and reassess positions. Recent earnings have generally trended negative, with the last report producing a sharp decline that has continued into the current setup.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 21.11% (approximately $1.90) by the April 17 expiration, suggesting a range between $7.12 and $10.92. This is substantially higher than the historical average Day 0 move of 6.93%, indicating options traders are anticipating significantly more volatility than the stock has typically delivered. The elevated implied volatility of 94.90% reflects heightened uncertainty around this release, likely driven by concerns about the widening losses and the stock's recent sharp decline.

Part 3: What Analysts Are Saying

Analyst sentiment on LENZ remains strongly bullish despite the stock's recent struggles, with 7 of 8 analysts rating the stock a Strong Buy and just 1 Hold rating. There are no Sell ratings. The average recommendation of 4.75 out of 5 reflects very high conviction, and this consensus has remained unchanged over the past month.

The average price target of $50.17 implies massive upside of 455% from the current price of $9.03, with targets ranging from a low of $35.00 to a high of $62.00. This wide disparity between the current stock price and analyst targets suggests the Street believes the market is significantly undervaluing LENZ's long-term potential, likely viewing the current losses as a temporary investment phase that will yield substantial returns once VIZZ gains commercial traction.

Recent analyst activity has focused on revising near-term estimates to reflect higher launch costs, but the bullish long-term view remains intact. The fact that no analysts have downgraded to Sell despite the stock's sharp decline and widening losses indicates confidence that the VIZZ opportunity justifies the current cash burn.

Part 4: Technical Picture

LENZ enters earnings in a deeply oversold technical position, with the Barchart Technical Opinion showing a 100% Sell signal—the maximum bearish reading. This signal has intensified from 88% Sell last week and matches the 100% Sell reading from a month ago, indicating sustained downward pressure.

Timeframe Analysis:

• Short-term (100% Sell): Maximum sell signal indicates severe near-term downward momentum heading into earnings
• Medium-term (100% Sell): Bearish intermediate-term trend suggests no relief in sight without a catalyst
• Long-term (100% Sell): Maximum long-term sell signal reflects a complete breakdown in the broader trend structure

Trend Characteristics: The Maximum Strongest bearish signal indicates LENZ is in an extreme downtrend with no technical support, creating a high-risk setup for earnings.

The stock is trading at $9.03, below all key moving averages: the 5-day ($10.74), 10-day ($11.39), 20-day ($12.10), 50-day ($14.35), 100-day ($18.80), and 200-day ($27.54). This complete breakdown below all moving averages confirms the severity of the technical damage.

The stock has lost 67% from its 200-day moving average, reflecting a catastrophic decline that has accelerated in recent months. While the extreme oversold condition could set up a technical bounce if earnings surprise positively, the lack of any support levels and the uniformly bearish technical picture suggest significant risk of further downside if results disappoint. The 21% expected move priced by options appears justified given the technical fragility and the high stakes around VIZZ launch metrics.